Rory Riggs has over 20 years of experience the creation and development of many successful companies the healthcare and financial services industries. These companies include: Royalty Pharma; Fibrogen, Inc.; Cibus, LLC; Sugen, Inc.; GeneNews and eReceivables. He is currently: CEO and Founder of Syntax LLC where he is applying clinical approaches to portfolio management, chairman and co-founder of Royalty Pharma, the largest investor in revenue-producing intellectual property, principally royalty interests in marketed and late-stage development biopharmaceutical product; Chairman and Co-founder of Cibus, the leader in non-transgenic (non-GMO) gene editing in agriculture. He also served as the president and director of Biomatrix Corporation (NYSE: BXM) where he launched Synvisc, an important product in the treatment of osteoarthritis.
Rory is a managing member and sits on the boards of managers of New Ventures I, LLC, New Ventures Select and New Ventures III, LLC. Rory received a BA from Middlebury College and an MBA from Columbia University.
Back to Partners